Evidence map›Paper›PMID 32871771›Full record

ArticleIn vivo (Athens, Greece)

The Role of SNPs in

Alvita Vilkeviciute, Neringa Bastikaityte, Ruta Mockute, Dzastina Cebatoriene, Loresa Kriauciuniene, Jurate Balciuniene, Reda Zemaitiene, Rasa Liutkeviciene

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Cells · 2022
    Article
  4. Medicina (Kaunas, Lithuania) · 2021
    Article
  5. Mediators of inflammation · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alvita VilkeviciuteNeuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania alvita.vilkeviciute@lsmuni.lt.
Neringa BastikaityteLithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.
Ruta MockuteDepartment of Ophthalmology, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.
Dzastina CebatorieneDepartment of Ophthalmology, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.
Loresa KriauciunieneNeuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.
Jurate BalciunieneDepartment of Ophthalmology, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.
Reda ZemaitieneDepartment of Ophthalmology, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.
Rasa LiutkevicieneNeuroscience Institute, Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania.
Lithuanian University of Health Sciences · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAge-related macular degeneration (AMD) affects the central part of the retina and causes blindness. In developed countries, AMD occurs in people over 50 years old. Important factors for AMD pathogenesis are an immune response, inflammation, and genetic factors. This study aimed to determine the impact of IL1RL1 rs1041973 and IL1RAP rs4624606 single nucleotide polymorphisms (SNPs) on the occurrence of AMD and the outcome of treatment with aflibercept and bevacizumab. PATIENTS AND

methods563 patients with AMD and 281 healthy candidates were evaluated. Patients with exudative AMD were treated with intravitreal bevacizumab and aflibercept and, after 6 months based on the changes in best-corrected visual acuity and central macular thickness, were classified as 'responders' or 'poor-responders'. Genotyping of IL1RL1 rs1041973 and IL1RAP rs4624606 was accomplished using real-time PCR. Age was compared using the Mann-Whitney U-test. Categorical data (gender, genotype, and allele distributions) compared between groups using the χ

resultsStatistically significant differences in the distribution of IL1RAP rs4624606 genotypes (TT, TA and AA) were found between males with atrophic AMD and controls: 50%, 42.9% and 7.1% vs. 69.7%, 30.3% and 0%, respectively, p=0.015. Moreover, we found that 'responders' had a significantly better best-corrected visual acuity than 'poor-responders' before treatment (p=0.032). The central macular thickness was significantly lower in exudative AMD patients with IL1RL1 rs1041973 AA genotype than in wild type and heterozygous (CC+CA) genotype carriers before treatment (p=0.017).

conclusionIL1RAP rs4624606 may be associated with atrophic AMD in males while IL1RL1 rs1041973 may play a protective role against macular thickening in exudative AMD patients.

Indexed as

Interleukin-1 Receptor Accessory ProteinInterleukin-1 Receptor-Like 1 ProteinMacular DegenerationPolymorphism, Single NucleotideBevacizumabGenotypeHumansMaleMiddle AgedTreatment OutcomeBevacizumabIL1RAP protein, humanIL1RL1 protein, humanInterleukin-1 Receptor Accessory ProteinInterleukin-1 Receptor-Like 1 ProteinAge-related macular degenerationgene polymorphismsIL1RAP rs4624606IL1RL1 rs1041973treatment

Identifiers

PMID32871771
PMCPMC7652449
OpenAlexW3082374804

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.